Methods and compositions for treating cancers

Patent metadata

Field	Value
Publication number	US-11458194-B2
Application number	US-201716303705-A
Country	US
Kind code	B2
Filing date	May 24, 2017
Priority date	May 25, 2016
Publication date	Oct 4, 2022
Grant date	Oct 4, 2022

Abstract

The inventors have developed a metastatic 4T1 breast tumor model in BALB/c mice. They have shown that the vaccination with xenogeneic embryonic stem cells in combination with valproic acid (VPA) generates a higher anti-tumoral response against breast cancer and inhibits metastasis development. They established that these responses are achieved only by the addition of valproic acid in the therapeutic regimen in comparison to the use ESCs or iPSCs alone. Thus, the inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to i) a population of pluripotent cells and ii) a compound selected from a group which activates MHC expression, as a combined preparation for use in a method for treating a subject suffering from a cancer, comprising a step of administering simultaneously, separately or sequentially to said subject a therapeutically amount thereof.

First claim

The invention claimed is:

1. A method for treating cancer in a subject, comprising the step of administrating simultaneously, separately or sequentially to said subject a therapeutically amount of (i) a histone deacetylase inhibitor (HDACi) and (ii) a vaccine composition containing a population of pluripotent cells that have been inactivated.

2. The method of claim 1 , further comprising the step of administering an HDACi for a period of time after the administration of the vaccine composition.

3. The method of claim 1 , wherein the cancer is selected from liver cancer, bladder carcinoma, breast carcinoma, cervical carcinoma, cholangiocarcinoma, colorectal carcinoma, gastric sarcoma, glioma, lung carcinoma, lymphoma, acute and chronic lymphoid and myeloid leukemias, melanoma, multiple myeloma, osteosarcoma, ovarian carcinoma, pancreatic carcinoma, prostate carcinoma, stomach carcinoma, kidney carcinoma, a head and neck tumor, and a solid tumor.

4. The method of claim 1 , further comprising performing one or more of radiation therapy, targeted therapy, immunotherapy, or chemotherapy to the subject.

5. The method of claim 1 , wherein the pluripotent cells are selected from human embryonic stem cells, induced pluripotent stem cells (iPS), allogeneic stem cells, xenogeneic stem cells, autologous stem cells and syngeneic stem cells.

6. The method of claim 1 , wherein the administration of the pluripotent cells is performed by intradermal, intravenous, subcutaneous, or intramuscular injection.

Assignees

• Inst Nat Sante Rech Med
• Hopitaux Paris Assist Publique
• Univ Paris Saclay
• Univ Paris
• Assist Publique—Hopitaux De Paris Aphp
• Univ Paris Cite

Inventors

• Griscelli Frank
• Turhan Ali
• Bennaceur Griscelli Annelise

Classifications

• A61K31/19 Primary

  Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title

• A61K35/545

  Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells · CPC title

• A61K2039/55511

  Organic adjuvants · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title